Novartis’ $12bn Avidity bet falters on late-stage del-desiran flop
Phase 3negativedel-desiranNegative
AI Analysis
Summary
Novartis' $12 billion acquisition of Avidity is challenged after the late-stage HARBOR trial for del-desiran failed, undermining a key justification for the acquisition price.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
HARBOR trial failure
Importance:8/10
Sentiment:
-0.90
late-stage failurePhase 3acquisitiondel-desiranHARBOR trial
Read the original article
Published by Clinical Trials Arena on September 8, 2026 9:50 AM